When Do GLP-1 Patents Expire? The Complete Generic Timeline

In the U.S., two older GLP-1 drugs already have generics: liraglutide (Victoza and Saxenda) and exenatide (Byetta). Generic semaglutide (Ozempic, Wegovy, and Rybelsus) is unlikely before about 2031 to 2032. The main patent on tirzepatide (Mounjaro and Zepbound) runs to May 13, 2036. These later dates are projections from patent records. Court rulings or private settlements could move them.

Four different things set these dates. A patent expiry is the day a company's legal monopoly on an invention ends, and the FDA lists drug patents in its Orange Book. Regulatory exclusivity is a separate period of protection tied to FDA approval. Dulaglutide is a biologic, a protein drug made in living cells, so its copies would be biosimilars: close copies approved through their own pathway. Lawsuits can freeze approvals. Generic makers ask the FDA to approve a copy by filing an abbreviated new drug application, or ANDA. Lilly sued the companies that filed for tirzepatide. Under federal law, that blocks final FDA approval until about November 2029 unless a court rules first. Actual availability comes last. A generic launches only when patents, exclusivity, lawsuits, and settlement terms all allow it. The launch dates in Novo's Ozempic settlements are not public.

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but access remains severely limited by cost. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) still carry US list prices above $1,000 a month, although direct-to-consumer prices for many doses fell to $149 to $449 a month in 2026. For millions of patients, the practical question isn't which GLP-1 is best — it's when will I be able to afford one?

The answer depends on patent expiration dates, and those dates vary dramatically by drug, by country, and by how aggressively manufacturers defend their patent portfolios. According to I-MAK, a patent watchdog group, Novo Nordisk has filed 320 US patent applications for semaglutide alone, with 154 granted and follow-on patents that could extend protection to 2042. Understanding this landscape is essential for anyone planning long-term GLP-1 therapy.

GLP-1 drugs differ a lot in how much weight people lose. The gap between the cheapest generic option and the newest patent-protected drugs is large, which is exactly why patent timelines matter so much.

The table shows average weight loss in each drug's main obesity trial, counting everyone who was randomized, next to the placebo group. The trials differed in length and design, so treat the numbers as a rough guide rather than a ranking.

Liraglutide is the first-generation daily injection and the only drug here with US generics for weight loss. Semaglutide comes as a weekly shot (Wegovy) and, since December 2025, as a daily pill. Tirzepatide, which acts on both GIP and GLP-1 receptors, produces more weight loss than semaglutide but has the longest US patent runway. CagriSema adds the amylin drug cagrilintide to semaglutide. Retatrutide, which also acts on the glucagon receptor, has produced the largest weight loss in this class so far; counting only the time people stayed on the drug, its top dose reached about 28%.

The pattern is clear: the most effective drugs are also the ones with the longest patent protection. In these trials, generic liraglutide delivered about a third of the weight loss seen with tirzepatide. For patients choosing between an affordable generic and a patent-protected brand, that difference matters.

Liraglutide (Victoza for diabetes, Saxenda for weight loss) became the first GLP-1 receptor agonist sold as a generic in the US. Teva launched an authorized generic of Victoza, made under license from Novo Nordisk, in June 2024. The first FDA-approved copy of Victoza from another company, made by Hikma, followed in December 2024.

For weight loss, the FDA approved Teva's generic Saxenda in August 2025, and Biocon and Orbicular won approval for their versions in February 2026. The FDA's Orange Book now lists generic liraglutide from nine companies, including Lupin, Fresenius Kabi, Mylan, and Sandoz.

The first price cuts were modest: generic liraglutide launched at about $1,165 a month, compared with $1,300 to $1,800 for brand Saxenda. More competitors usually push prices down over time.

Liraglutide is an older daily injection with smaller weight loss than the newer drugs. But as more makers compete, it may become the default starting point for patients who cannot get or afford semaglutide or tirzepatide.

Semaglutide is where things get complicated, and where the most money is at stake.

In the US, the FDA's Orange Book lists two compound patents on the molecule. The first, US Patent No. 8,536,122, expired on March 20, 2026. The second, US Patent No. 8,129,343, runs to December 5, 2031 after extensions. Novo Nordisk's 2025 annual report gives 2032 as the US compound patent expiry for Ozempic, Rybelsus, and Wegovy. Dozens of later patents cover formulations, pens, and uses, and the latest one listed in the Orange Book runs to 2041.

Generic makers have already challenged those patents. Novo settled its Ozempic patent cases with Mylan, Sun Pharma, Dr. Reddy's, Zydus, Apotex, Alvogen, and Rio. The terms are confidential, so the agreed US launch dates are not public.

Outside the US, generics arrived in 2026:

• Canada. Novo's main Canadian patent lapsed early after a maintenance fee went unpaid, and data protection ended in January 2026. Health Canada approved Dr. Reddy's generic Ozempic on April 28, 2026 and Apotex's on May 1, and both launched on May 14. An Apotex generic for weight loss was approved on June 29, and Sandoz won approval in September. See our Canadian generic semaglutide pricing guide.
• India. The core patent expired on March 20, 2026. By March 21, Dr. Reddy's, Zydus, Alkem, Sun Pharma, and Glenmark had launched generics, several priced at about INR 1,800 to 4,200 a month.
• Brazil. The patent expired in March 2026, and the regulator Anvisa approved EMS's Ozivy pen in May.
• China. The core patent expired on March 20, 2026, with 12 copies from 10 Chinese companies awaiting review. None had been approved on that date, and we could not confirm an approval as of early October 2026.

These products are not legal to import into the US for routine use. Our international price comparison shows how far prices have fallen abroad.

I-MAK estimates that Novo Nordisk will earn $166 billion in US semaglutide revenue from 2026 through 2031, which helps explain the size of its patent portfolio.

Oral semaglutide has extra layers of protection. Its absorption enhancer, called SNAC, has its own patents, and the latest patents listed for the Wegovy pill and Rybelsus run to February 2039. Generic makers would need a different way to get the drug absorbed, or they would have to wait.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) has the most distant generic timeline among approved GLP-1 drugs.

The main compound patent, US Patent No. 9,474,780, runs to May 13, 2036, according to the Orange Book. Later patents on formulations and uses run to December 2041. Lilly's 2025 annual report lists 2036 for the US compound patent and 2037 for major European countries.

Generic makers could file patent challenges starting May 13, 2026, four years after Mounjaro's approval, and several did. The FDA accepted Sandoz's two applications on June 29, 2026 and Amneal and Adalvo's on July 8. China's Hybio announced its own filings in July. In August, Lilly sued 14 generic companies in federal court in Delaware.

Because these challenges came in the drug's fifth year on the market and Lilly sued in time, federal law stretches the usual 30-month freeze on FDA approval to 7.5 years after Mounjaro's May 2022 approval. That means no final FDA approval before about November 2029 unless a court rules for the generic makers first. Even after that, a generic could not launch before the 2036 patent expiry unless the generic makers win in court or reach a settlement with Lilly. Our generic tirzepatide timeline covers the details.

Exenatide (Byetta) has a US generic: the FDA approved Amneal's version in November 2024. As the oldest GLP-1 drug, injected twice a day, it is rarely started in new patients.

Dulaglutide (Trulicity) is a larger protein drug regulated as a biologic, so copies would be biosimilars rather than generics. Lilly's 2025 annual report lists 2027 as the end of both its US compound patent and its biologics data protection, so biosimilar dulaglutide could follow after that.

Retatrutide (Eli Lilly) is not yet approved. Lilly said in July 2026 that it plans to file for FDA approval in the first quarter of 2027. Lilly has also asked the FDA to classify retatrutide as a biologic rather than a standard drug, which would bring 12 years of market exclusivity instead of 5. The dispute turns on how to count the amino acids in the molecule, because the FDA treats peptides of 40 amino acids or fewer as drugs. In fall 2025, a federal court in Indiana sent the question back to the FDA for a better explanation.

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, a new amylin drug. The semaglutide half follows the existing patent timeline, but cagrilintide carries its own patents, which Novo lists as running to 2037.

The GLP-1 market exemplifies a broader pharmaceutical strategy known as "patent thicketing" — filing large numbers of follow-on patents for minor modifications to extend market exclusivity well beyond the original compound patent.

To understand why this matters, it helps to know how drug patents work. The original "compound patent" covers the molecule itself — semaglutide, the chemical entity. This is the foundational patent, and for semaglutide it would have expired in March 2026. But manufacturers can file additional "follow-on" patents that cover everything around the molecule: specific formulations (how it's mixed and stabilized), delivery devices (the pen injector design), dosing regimens (the specific titration schedule), methods of treatment (using semaglutide for obesity vs. diabetes vs. cardiovascular risk), and manufacturing processes. Each of these can carry its own 20-year patent term. A generic manufacturer must either design around every active follow-on patent or wait for them all to expire — even if the molecule itself is off-patent.

Novo Nordisk's semaglutide portfolio illustrates the scale. I-MAK counts 320 patent applications, 154 of them granted. The breakdown: 91 formulation patents, 41 delivery device patents, and 45 method-of-treatment patents. The original compound protection would have expired in 2026; the thicket extends potential protection to 2042 — 16 additional years of exclusivity built on patents that cover not the molecule, but everything surrounding it.

For patients, this means the price relief that patent expiration normally brings may be delayed by a decade or more — even when the fundamental molecule is no longer novel. Advocacy organizations like I-MAK have documented this pattern across the GLP-1 class, arguing it represents a form of patent abuse that keeps prices artificially high.

The full landscape, drug by drug:

The practical picture right now.

Available generics: liraglutide and exenatide.

Available outside the US: generic semaglutide in Canada, India, and Brazil, with China expected to follow. These products are not legal to import into the US for routine use.

Years away in the US: generic semaglutide (around 2031–2032 at the earliest), generic oral semaglutide (later, because of patents running to 2039), and generic tirzepatide (2036 unless litigation or a settlement changes it).

Lower brand prices are arriving first. Novo Nordisk plans to cut the US list price of Wegovy and Ozempic to $675 a month on January 1, 2027. On the same date, Medicare's negotiated price for semaglutide, $274 for a 30-day supply, takes effect. Self-pay prices have also fallen: as of early September 2026, the Wegovy pill started at $149 a month and Zepbound vials cost $299 to $449 through LillyDirect. Our TrumpRx guide covers these deals.

Compounding is narrowing. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk ingredients that large compounding plants (called 503B outsourcing facilities) may use. The comment period closed on July 30, and we found no final decision as of early October. Smaller 503A pharmacies, which fill one prescription at a time, face their own limits. See our compounded GLP-1 pricing guide.

The bottom line: in the US, the cheapest routes in 2026 come mostly from brand discounts and Medicare deals, not from generics. Generic liraglutide is the only generic option for weight loss. If you are waiting for generic semaglutide or tirzepatide, plan on years, not months, unless patent cases or new laws change the timeline.

Update (October 5, 2026): We added the 2026 generic semaglutide launches in Canada, India, and Brazil, and the status in China. We added the tirzepatide patent challenges filed from May 2026 and Lilly's August 2026 lawsuits against 14 generic makers. We also added Novo's 2027 list-price cut, Medicare's negotiated semaglutide price, and the FDA's April 2026 proposal on 503B compounding. Patent dates now come from the FDA's Orange Book and the companies' 2025 annual reports.

Update (October 5, 2026): We added a summary of U.S. generic timing at the top of the article.

Correction (October 5, 2026): The original version said tirzepatide's main US compound patent expires in January 2036. The Orange Book lists May 13, 2036. It said Canada's semaglutide patents expired on January 4, 2026. That date marked the end of data protection; the main Canadian patent had lapsed earlier. It listed "oral semaglutide 50 mg (Rybelsus)" at 12.7% weight loss. The oral weight-loss product is the 25 mg Wegovy pill, and the table now shows each drug's main trial result next to placebo. We removed a claim that dulaglutide would go generic, since it is a biologic and copies would be biosimilars. We also removed a figure for Lilly's 2025 manufacturing spending that we could not verify.